Keynote 811 Update

from OncoPharm · host John Bossaer

The updated Keynote 811 OS results convert an accelerated approval for pembrolizumab to a regular approval, albeit restricted by PD-L1 CPS status of 1 or higher.

Episode metadata supplied by the publisher feed · Published Mar 19, 2025

Embed this episode

Attribution link and audio player

Ready to play

Keynote 811 Update

0:00 12:59

1×

No transcript for this episode yet

We transcribe on demand. Request one and we'll notify you when it's ready — usually under 10 minutes.

Share this episode

Similar Episodes

No similar episodes found.

Similar Podcasts

No similar podcasts found.

Frequently Asked Questions

How long is this episode of OncoPharm?

This episode is 12 minutes long.

When was this OncoPharm episode published?

This episode was published on March 19, 2025.

Can I download this OncoPharm episode?

Yes. Use the download control on the episode player to save the publisher-provided media file.

URL copied to clipboard!